Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

University of Calgary

$24,000.00

Novel platforms for detection of Mycobacterium avium subsp. paratuberculosis infection in dairy cattle.

EF 2018-19

Résumé
Johne's disease (JD), a debilitating chronic enteritis in ruminants caused by Mycobacterium avium subsp. paratuberculosis (Map), is one of the main health issues in the dairy industry, resulting in significant economical impact. Prevention and control programs are severely hampered by the poor performance of current diagnostic tests, especially in the early stages of the infection. They fail to reliably detect infected animals before they can spread the disease. Current ELISAs for antibody (Ab) testing have crude antigen (Ag) mixtures that are not optimized for early detection. Fecal shedding and Ab responses correlate poorly, but combined testing for these increases testing sensitivity.*The goal of this research program is to improve current JD diagnostics and develop a complementary panel of on-farm diagnostics that can detect viable Map bacteria or specific Abs with higher sensitivity, allowing culling/segregation and reducing the spread of the disease by test-and-cull strategies. Our two proposed test platforms are compatible with multiple testing requirements of comprehensive control programs.*The first platform will measure Ab responses against Map. The key innovation of the first platform is that pathogen specific Ab restore activity of a reporter enzyme that was split in half. This is accomplished by fusing Ags to each half of this enzyme and by including a protein -an intein- that can ligate the fragments back together. Trehalase was selected as novel reporter because of its high activity and compatibility with inexpensive glucosemeters for detection. In a tiered approach, we will first incorporate a well characterized immunogenic epitope in this assay, then known Map antigenic peptides and next we will use the platform to discover new Map Ags for earlier and more sensitive and specific detection of Map infections.*The second platform will use engineered bacteriophages to detect viable Map cells. Detection of viable Map directly correlates with infectivity and eliminates uncertainty associated with low level detection by current qPCR methods. The technology relies on the fact that phages only amplify within living cells. We are improving this method by introducing a genetic switch that is activated during replication. This signature genetic switch can be easily detected and quantified and distinguishes replicated phages from phages added to the sample. This will also allow more accurate quantification and increase the sensitivity of phage-based detection of viable MAP.*In summary, our new platforms provide solutions to all the crucial difficulties hampering current JD diagnostics. The development of complementary assays that can be performed on-farm, will dramatically increase the sensitivity of detecting infected animals and thereby improve JD control programs. The diagnostic platforms have a
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
RGPIN-2015-04607
Name nom
DeBuck, Jeroen
Department département
Veterinary Medicine, Faculty of
Organization id
11
Institution établissement
University of Calgary
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2015
Award amount
24000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1502
Committee name en
Biological Systems and Functions
Committee name fr
Systèmes et fonctions biologiques
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5305
Research subject group en
Molecular biology
Research subject group fr
Biologie moléculaire
Research subject en
Protein manipulation and expression
Research subject fr
Expression et recombinaison protéiques
Partie
4
Nb partie
5
Application title
Novel platforms for detection of Mycobacterium avium subsp. paratuberculosis infection in dairy cattle.
Keyword
NSERC
Application summary
Johne's disease (JD), a debilitating chronic enteritis in ruminants caused by Mycobacterium avium subsp. paratuberculosis (Map), is one of the main health issues in the dairy industry, resulting in significant economical impact. Prevention and control programs are severely hampered by the poor performance of current diagnostic tests, especially in the early stages of the infection. They fail to reliably detect infected animals before they can spread the disease. Current ELISAs for antibody (Ab) testing have crude antigen (Ag) mixtures that are not optimized for early detection. Fecal shedding and Ab responses correlate poorly, but combined testing for these increases testing sensitivity.*The goal of this research program is to improve current JD diagnostics and develop a complementary panel of on-farm diagnostics that can detect viable Map bacteria or specific Abs with higher sensitivity, allowing culling/segregation and reducing the spread of the disease by test-and-cull strategies. Our two proposed test platforms are compatible with multiple testing requirements of comprehensive control programs.*The first platform will measure Ab responses against Map. The key innovation of the first platform is that pathogen specific Ab restore activity of a reporter enzyme that was split in half. This is accomplished by fusing Ags to each half of this enzyme and by including a protein -an intein- that can ligate the fragments back together. Trehalase was selected as novel reporter because of its high activity and compatibility with inexpensive glucosemeters for detection. In a tiered approach, we will first incorporate a well characterized immunogenic epitope in this assay, then known Map antigenic peptides and next we will use the platform to discover new Map Ags for earlier and more sensitive and specific detection of Map infections.*The second platform will use engineered bacteriophages to detect viable Map cells. Detection of viable Map directly correlates with infectivity and eliminates uncertainty associated with low level detection by current qPCR methods. The technology relies on the fact that phages only amplify within living cells. We are improving this method by introducing a genetic switch that is activated during replication. This signature genetic switch can be easily detected and quantified and distinguishes replicated phages from phages added to the sample. This will also allow more accurate quantification and increase the sensitivity of phage-based detection of viable MAP.*In summary, our new platforms provide solutions to all the crucial difficulties hampering current JD diagnostics. The development of complementary assays that can be performed on-farm, will dramatically increase the sensitivity of detecting infected animals and thereby improve JD control programs. The diagnostic platforms have a